Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM9N8WM)

Drug Name
Ciproxifan Drug Info
Synonyms
ciproxifan; 184025-18-1; FUB-359; FUB 359; FUB359; UNII-5EVQ7IRG99; 5EVQ7IRG99; CHEMBL14638; ACQBHJXEAYTHCY-UHFFFAOYSA-N; cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone; (4-(3-(1H-imidazol-4-yl)propoxy)phenyl)(cyclopropyl)methanone; Ciproxifan; FUB 359; Methanone, cyclopropyl(4-(3-(1H-imidazol-5-yl)propoxy)phenyl)-; Ciproxifan (FUB-359); AC1O4Y0P; GTPL1265; SCHEMBL3335184; BDBM27213; EX-A077; DTXSID50171532; cyclopropyl-(4-(3-1H-imidazol-4-yl)propyloxyphenyl)ketone; CHEBI:125467; MolPort-027-720-958; ZINC1892860
Cross-matching ID
PubChem CID
6422124
ChEBI ID
CHEMBL14638
CAS Number
CAS 184025-18-1
TTD Drug ID
D0I3XA

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Influenza A -1.63 4.71e-2 156/172 (90.7%) TRADD;HLA-DRA;IFNGR2;...
Linoleic acid metabolism -1.63 4.84e-2 21/29 (72.41%) CYP3A4;PLA2G5;CYP2E1;...
Non-alcoholic fatty liver disease -1.65 4.28e-2 126/155 (81.29%) IL1A;BID;MAP3K5;...
Rheumatoid arthritis -1.65 4.48e-2 78/93 (83.87%) CSF1;ATP6V0A2;HLA-DOA;...
Chemokine signaling pathway -1.70 2.80e-2 163/192 (84.9%) CCL4;AKT3;CCR5;...
Inflammatory bowel disease -1.70 2.90e-2 58/65 (89.23%) HLA-DOA;HLA-DOB;GATA3;...
Retinol metabolism -1.70 3.06e-2 41/68 (60.29%) CYP2C8;CYP3A7;DHRS9;...
Coronavirus disease -1.71 3.08e-2 215/232 (92.67%) AGTR1;FAU;CSF2;...
Leishmaniasis -1.71 3.27e-2 67/77 (87.01%) HLA-DOA;HLA-DOB;TRAF6;...
Hematopoietic cell lineage -1.72 3.23e-2 90/99 (90.91%) IL7R;CD7;CSF1;...
Intestinal immune network for IgA production -1.72 3.19e-2 38/48 (79.17%) HLA-DOA;ICOS;HLA-DOB;...
Toll-like receptor signaling pathway -1.73 3.36e-2 94/104 (90.38%) RELA;MAP2K4;TLR3;...
Systemic lupus erythematosus -1.74 3.17e-2 45/135 (33.33%) HLA-DOA;C9;HLA-DOB;...
Allograft rejection -1.76 2.94e-2 32/38 (84.21%) HLA-DOA;HLA-DOB;HLA-DRA;...
Viral myocarditis -1.77 3.04e-2 53/60 (88.33%) HLA-DPB1;HLA-DMB;HLA-DQB1;...
Oxidative phosphorylation -1.78 2.96e-2 93/133 (69.92%) ATP5F1C;ATP6V0A2;PPA2;...
Porphyrin and chlorophyll metabolism -1.85 1.90e-2 23/43 (53.49%) FECH;BLVRB;PPOX;...
Asthma -1.96 5.43e-3 25/31 (80.65%) HLA-DOA;HLA-DOB;HLA-DRA;...
Pertussis -1.97 4.75e-3 64/76 (84.21%) CASP1;C3;GNAI1;...
Graft-versus-host disease -1.99 3.80e-3 32/42 (76.19%) HLA-DOA;HLA-DOB;KLRD1;...
Viral protein interaction with cytokine and cytokine re... -2.04 2.38e-3 84/100 (84%) IL18R1;IL10RB;CCL19;...
Complement and coagulation cascades -2.20 0.00e+0 76/85 (89.41%) VWF;C3AR1;THBD;...
Legionellosis -2.22 0.00e+0 51/57 (89.47%) RELA;HSPA1A;BNIP3;...
Staphylococcus aureus infection -2.43 0.00e+0 72/95 (75.79%) DEFA4;KRT15;HLA-DRA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H